Navigation Links
Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
Date:10/23/2008

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that an abstract entitled "A Phase I Study to Evaluate Systemic Wild-Type Reovirus (REOLYSIN(R)) in Combination with Docetaxel in Patients with Advanced Malignancies" will be available in the November/December issue of the Journal of Immunotherapy, the official journal of the International Society for Biological Therapy of Cancer (iSBTc). The principal investigator for the trial is Professor Hardev Pandha of the Royal Surrey County Hospital, U.K.

The abstract covers results of the trial (REO 010) up to July 2008. Of the 12 patients treated at the time, three had completed six cycles, one further patient was still on treatment at cycle 7 and four others were ongoing between cycle 1 and cycle 4. Five patients remained on study. The researchers observed one complete resolution of the target lesion in a breast cancer patient with stable disease (SD) of non-target lesions; one partial response in gastric cancer; two SD in lung cancer; and, one SD in melanoma. The researchers concluded that REOLYSIN(R) can be safely combined with docetaxel, that there was objective radiological evidence of anticancer activity and that Phase II studies with this combination are justified. Any significant toxicities observed were consistent with those expected with docetaxel alone.

A poster presentation which will include current results of the trial is scheduled to be presented by Prof. Pandha on November 1, 2008 at the iSBTc annual meeting. The meeting is being held in San Diego, California from October 31-November 2, 2008.

Prof. Pandha is also scheduled to make a poster presentation on November 1, 2008 at the iSBTc meeting entitled "Synergistic Anti-Tumour Activity of Oncolytic Reovirus and Docetaxel in a PC-3 Prostate Cancer Mouse Model." This preclinical research, which demonstrated that combining reovirus and docetaxel treatment resulted in markedly re
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
2. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
3. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
4. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
5. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
6. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
7. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
8. Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
10. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., Whether it,s CD packaging, containers or iden...ification) are increasingly finding their way into...ects or goods and identify them automatically by r...nd process the data contained in the label. Smart ...nditions of up to 100 degrees Celsius. But at high...
(Date:11/24/2009)...v. 24 Dow AgroSciences C...f Hyland Seeds, a division of Thompsons Limited of...ill further expand Dow AgroSciences, current seeds...ion of SmartStax(TM) in 2010 and Dow AgroSci...in 2012. The transactional close is expected in th...
(Date:11/24/2009)...ire-Asia/ -- NOD Pharmaceuticals Inc. announced,th...ed the patent application for,its nano-particle or...nology is a highly efficient approach to incorpora...ticles to enable oral delivery of drugs,otherwise ...atform technology,that can be applied to many macr...
(Date:11/24/2009)...as been met for patients with advanced-stage, o..., Nov. 24 /PRNewswire-FirstCall/ - AEterna Zentari... a global biopharmaceutical company focused on end...ive efficacy data from a Phase 2 study with its ta...erly AN-152), in patients with advanced or recurre...
Breaking Biology Technology:Intelligence inside metal components 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...(Nasdaq: VRUS ) management will present at the 3r...2008, at the Citi Executive Conference Center, New...gan Stanley Global,Healthcare Unplugged Conference...ew York, NY. Schaefer Price, Pharmasset,s Chief Ex...he company followed by a question and,answer sessi...
...ESMO Congress,in Stockholm, the premier European c... medical oncologists, as well as a focal point to ...nes., The Congress Centre will be the venue for i...nd a place to discuss critical issues for,European...raining of young,oncologists and better integratio...
...rstCall/ -- Huifeng Bio-,Pharmaceutical Technology... leading developer and producer of plant extracts ...ceutical, nutraceutical and food production in,Xi,...nt to enter into a,contractual arrangement with Xi...e proposed terms of this arrangement, Huifeng will...
Other Biology Technology:Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences 233rd ESMO Congress in Stockholm, 12-16 September 2008 233rd ESMO Congress in Stockholm, 12-16 September 2008 333rd ESMO Congress in Stockholm, 12-16 September 2008 433rd ESMO Congress in Stockholm, 12-16 September 2008 5Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xi'an Qinba Xintong Medical Ltd. 2
(Date:11/24/2009)... been prescribed by traditional healers in Brazil ...omach pain to fever and flu. , Now for the first ...n able to scientifically prove the pain relieving ... Brazilian mint. , Testing this ancient South Ame...ciela Rocha was able to show that when prepared as...
(Date:11/24/2009)...remarkable class of ring-shaped protein motors has...erkeley National Laboratory (Berkeley Lab) using a... at the Advanced Light Source (ALS). These protein...replication, and are vital to the survival of all ...ch as the human papillomavirus, which has been lin...
(Date:11/24/2009)...2009) New research on bacterial communities throu...edictable temporal patterns, suggesting that scien...onitoring climate change in the polar regions. The... the National Academy of Sciences Early Edition, ... shifted synchronously over time, correlating with...
Breaking Biology News(10 mins):Got a pain? -- Have a cup of Brazilian mint 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2Top Healthcare Magazine Awards Carefx Client 2009 IT Project of the Year 53045 1Top Healthcare Magazine Awards Carefx Client 2009 IT Project of the Year 53045 2Top Healthcare Magazine Awards Carefx Client 2009 IT Project of the Year 53045 3MUSA Technology Partners Introduces Linux Open Source Service Desk 13245 1MUSA Technology Partners Introduces Linux Open Source Service Desk 13245 2MUSA Technology Partners Introduces Linux Open Source Service Desk 13245 3American Academy of Dermatology to Hold Summer Scientific Meeting in Boston 53038 1
...archer at the Hebrew University of Jerusalem has s...urons in the brain of a mammal. , Dr. Adi Mizrahi...r Silberman Institute of Life Sciences at the Hebr...ons, or nerve cells, develop from an undifferentia...This has great significance for the future of brai...
... a new gene therapy can nearly eliminate arthritis...o the affected joints, according to a study publis... While the study was done in mice, they are the fi...is like humans, with the same genetic predispositi...ase, the authors said. If all goes well with a fol...
...k could soon be roaming our pastures, reports Cath...ine of the SCI. Scientists in New Zealand have di...a natural ability to produce skimmed milk and plan... producing only skimmed milk. , The researchers a...with the unique characteristics required to make a...
Other Biology News:A first -- Hebrew University scientist observes brain cell development in 'real time' 2Experimental gene therapy 'abolishes' arthritis pain and lessens joint damage 2Experimental gene therapy 'abolishes' arthritis pain and lessens joint damage 3Experimental gene therapy 'abolishes' arthritis pain and lessens joint damage 4Skimmed milk -- Straight from the cow 2
...is an enzymeimmunoassay intended for the quantitat... and other hydroxylated metabolites in human serum...liminates the inconvenience of solvent precipitati...tomation on many ELISA processors. The kit enables...
...h agarose suitable for a wide range of molecular b...d to Pulsed Field Gel Electrophoresis (PFGE). Due ...ti ABgarose can effectively separate large DNA fra...ans reduced band diffusion, a problem often associ...
Mouse Anti-Yersinia pestis F1 antigen Monoclonal Antibody, Unconjugated, Clone 1.F.1 from Abcam
Rabbit Anti-L Kynurenine Polyclonal Antibody, Unconjugated from Abcam
Biology Products: